세계의 REBOA(소생적 대동맥내 풍선 차단) 시장 : 규모, 점유율, 동향 분석 보고서 - 용도별, 지역별, 부문별 예측(2024-2030년)

Market Size & Trends:

The global resuscitative endovascular balloon occlusion of the aorta market size was valued at USD 9.58 million in 2023 and is projected to grow at a CAGR of 19.9% from 2024 to 2030. The market is driven by several key factors that influence its growth and adoption in clinical settings. These drivers include the increasing prevalence of traumatic injuries, advancements in medical technology, a growing emphasis on trauma care protocols, rising awareness among healthcare professionals, and supportive government initiatives. Each of these elements plays a crucial role in shaping the market landscape and enhancing the utilization of REBOA as a life-saving intervention.

The rising incidence of traumatic injuries, particularly those resulting from road accidents, falls, and violence, is a significant driver for the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) market. As trauma cases often lead to hemorrhagic shock, the demand for effective resuscitation techniques has surged. REBOA provides a minimally invasive option that can be rapidly deployed in emergency situations, making it an attractive choice for trauma surgeons and emergency medical services. In June 2024, the World Health Organization reported that injuries, both unintentional and violence-related, significantly contribute to trauma, leading to 4.4 million deaths annually. Exposure to trauma, especially during childhood, can heighten the risk of mental health issues, substance abuse, chronic diseases, and social problems.

Technological advancements in medical devices have significantly enhanced the efficacy and safety of REBOA procedures. Innovations such as improved balloon designs, better catheter systems, and enhanced imaging technologies facilitate more precise placement and monitoring during procedures. These advancements not only improve patient outcomes but also encourage healthcare providers to adopt REBOA as a standard practice in trauma care. In June 2024, Emergency Scientific, a Utah-based firm, announced the first use of its Landmark REBOA catheter, following its FDA 510(k) clearance. This device is for temporary occlusion of large vessels in emergency hemorrhage control. The Landmark catheter is designed to enhance the precision of occlusion while minimizing complications associated with traditional methods.

There is an increasing awareness among healthcare professionals regarding the benefits of REBOA in managing traumatic hemorrhage. Alongside this awareness, specialized training programs are being developed to educate clinicians on the proper use of REBOA techniques. This growing emphasis on education ensures that more healthcare providers are equipped with the knowledge and skills necessary to implement this life-saving procedure effectively. In March 2024, an article was published in the Journal of Emergency Medicine detailing A Pilot Study on A Novel REBOA Training Curriculum designed for Emergency Medicine Residents. This cutting-edge curriculum was designed to advance the competencies and understanding of Emergency Medicine residents in applying the REBOA technique, with the aim of bettering patient outcomes in life-threatening scenarios.

The regulatory environment surrounding medical devices has become increasingly supportive of innovative solutions like REBOA. Regulatory bodies are recognizing the importance of rapid intervention techniques in trauma care and are streamlining approval processes for new devices. This supportive stance encourages manufacturers to invest in research and development, further propelling market growth. In February 2024, Neurescue announced that it raised USD 7.27 million in a Series A funding round. This investment was spearheaded by West Hill Capital, a London-based investment firm.

Global Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global resuscitative endovascular balloon occlusion of the aorta market report based on end-use, and region:

• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Cardiac Arrest
• Aortic Occlusion
• Tactical Combat Casualty Care
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. End Use
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. End Use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of trauma cases
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Growing awareness and training programs
    • 3.2.1.4. Military applications
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Cost considerations
    • 3.2.2.2. Regulatory challenges
• 3.3. Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market: End Use Estimates & Trend Analysis

• 4.1. Global Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market: End Use Dashboard
• 4.2. Global Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market: End Use Movement Analysis
• 4.3. Global Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market Estimates and Forecasts, by End Use, Revenue (USD Million)
• 4.4. Cardiac Arrest
  • 4.4.1. Cardiac arrest market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Aortic Occlusion
  • 4.5.1. Aortic occlusion market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Tactical Combat Casualty Care
  • 4.6.1. Tactical combat casualty care market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Resuscitative Endovascular Balloon Occlusion of The Aorta (REBOA) Market: Regional Estimates & Trend Analysis by Application, Type, and End Use

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Vendor Landscape
  • 6.2.1. List of key distributors and channel partners
  • 6.2.2. Key customers
  • 6.2.3. Key company market share analysis, 2023
  • 6.2.4. Prytime Medical Devices, Inc
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. NEURESCUE
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Emergency Scientific, LLC
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Qx Medical
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Front Line Medical Technologies
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Reboa Medical As
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives